Advanced DPP technology for rapid animal-side detection of bovine tuberculosis

Award Information
Agency: Department of Agriculture
Branch: N/A
Contract: 2016-33610-25688
Agency Tracking Number: 2016-03778
Amount: $599,777.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: 8.3
Solicitation Number: N/A
Timeline
Solicitation Year: 2016
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-09-01
Award End Date (Contract End Date): 2019-08-31
Small Business Information
3661 HORSEBLOCK RD STE A, Medford, NY, 11763-0000
DUNS: 160348470
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Konstantin Lyashchenko
 Senior R&D Director
 (631) 924-1135
 kl@chembio.com
Business Contact
 Richard Larkin
Title: Chief Financial Officer
Phone: (631) 924-1135
Email: rlarkin@chembio.com
Research Institution
N/A
Abstract
Bovine tuberculosis (TB), a zoonotic disease caused by Mycobacterium bovis, continues to plague the cattle industry in the United States (US) and worldwide. Current diagnostic methods are inadequate; therefore, improved tests are urgently needed for disease control/eradication. The goal of the proposed research is to develop a simple, rapid, accurate, animal-side and cost-effective blood test for bovine TB in cattle. The assay will use Chembio proprietary Dual Path Platform (DPP) technology and rationally designed antigens of M. bovis to detect specific antibodies within 20 minutes under field conditions.Phase I studies have demonstrated the technical feasibility of the proposed approach. Several seroreactive antigens were identified which, when combined in our DPP assay, provided a diagnostic accuracy of ~95%. Proposed Phase II work has three technical objectives: 1) develop DPP BovidTB Assay, 2) evaluate test performance, and 3) validate the product in preparation for regulatory approval. Key antigen screening out of >100 novel M. bovis proteins will lead to designing efficient polyepitope fusion reagents for improved antibody detection. The DPP assay will be fully optimized and evaluated with extended panels of well-characterized serum specimens from cattle with confirmed M. bovis infection and from TB-free herds collected in the US, Brazil, the United Kingdom, and South Africa. Large-scale antigen production and DPP product manufacturing protocols will be validated. Portable optical readers will be evaluated to generate accurate quantitative data for objective DPP assay interpretation. Test performance evaluation results will be collected and analyzed to support regulatory submission.Upon successful completion of the Phase II work, Chembio will bring the new product to the US and international markets. The proposed research will be translated into significant commercial applications worldwide. The Chembio manufacturing facility in Medford, NY, is registered with FDA and licensed by USDA. The company has an extensive track record of new diagnostic product commercialization, including DPP VetTB Assay for captive cervids and elephants, and an established network of international distributors. A new blood test with superior performance and practical features will improve bovine TB control/eradication programs. Thus, the proposed research will meet the goals of the USDA Program Priorities and Societal Challenge Areas related to animal production and protection, and it will satisfy the public interest to increase food security and promote exports of agricultural biotechnology.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government